Background: The complement system plays a crucial role in acute xenogeneic reactions after cardiac transplantation. We used an ex vivo perfusion model to investigate the effect of Cp40, a compstatin analog and potent inhibitor of complement at the level of C3.
binding to other porcine antigens induce a delayed but strong humoral rejection. Antigen-antibody binding leads to rapid activation of the complement system. The classical (CP) and lectin pathways (LP) converge at the level of the CP/LP convertase C4b2b, whereas the alternative pathway (AP) culminates in the AP convertase C3bBb. Both convertases cleave C3, the central component of the complement system, to C3b and C3a. Amplification loops then follow, producing the anaphylatoxins C3a and C5a and resulting in the assembly of the cell-perforating terminal complement complex (TCC) (Fig. 1) . The activated complement system damages transplanted hearts by direct cell lysis and via signals that cause leukocyte infiltration; microthrombi are another undesirable consequence. 1, 2 Extended survival of transplants has been achieved using transgenic porcine hearts that express membrane-bound complement regulator proteins such as human CD46, CD55, CD59, or GGTA1-knockout organs that lack αGal. 3, 4 Systemic fluid-phase complement inhibition is needed to further reduce complement activation.
Compstatin is a peptide that selectively binds C3 and C3b and reversibly inhibits all downstream cell-surface complement components in humans and non-human primates ( Fig. 1 ), but does not affect nonprimates. [5] [6] [7] Structure-function refinement of compstatin has led to a series of analogs with improved inhibitory potency and pharmacokinetic profiles that show promise in many clinical applications and several primate models of disease. 8 The therapeutic C3 inhibitor Cp40 has been reported to inhibit complement-induced inflammation in cynomolgus monkeys triggered by hemodialysis filters. 9 Cp40
abrogates complement activation, conferring significant protection from inflammatory and procoagulation in septic animals. 10 Two further studies have described promising results with compstatin in the field of xenotransplantation, providing new insight into its therapeutic potential. Fiane et al. reported that compstatin prolongs survival of porcine kidneys perfused ex vivo with human blood. 11 Recently,
Kourtzelis et al. found that Cp40 abrogates endothelial activation
and leukocyte attachment in porcine endothelium exposed to human blood in vitro.
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Cp40 is specific for human and non-human primate C3, so only ex vivo perfusion models using primate (human) blood may serve as an alternative to non-human primate xenotransplantation models. We tested the effect of complement inhibition by Cp40 on a working porcine heart in a customized xenoperfusion system. These experiments enabled direct investigation of possible off-target toxic effects on the heart without confounding effects from off-target toxicity in other organs.
| MATERIAL AND METHODS

| Animals and anesthesia
Fifteen juvenile pigs (German Landrace; weight 15.0 ± 2.9 kg, blood group 0) were used as donors. Anesthesia was achieved with fen- 
| Surgical procedure and the biventricular heart perfusion system
A schematic representation of the ex vivo reperfusion system is shown in Fig. 2 . In brief, median sterno-/pericardiotomy was performed, followed by heparin administration, cross-clamping of the ascending aorta, and coronary infusion of histidine-tryptophan-ketoglutarate cardioplegia (HTK, 30 mL/kg body weight; Bretschneider solution ; compare with Fig. 8 )
Custodial, Dr. F. Köhler, Bernsheim, Germany) at 4°C. 13, 14 The hearts were topically cooled with ice-cold saline solution.
The ascending aorta and pulmonary artery trunk were cut and cannulas inserted. After mass ligation of both lung hila, the corresponding structures were transected distally. Both atria were cannulated, and the superior and inferior venae cavae were ligated and cut distally. The hearts were then removed and stored in lactated Ringer′s solution (Fresenius, Kabi, Bad Homburg, Germany) at 4°C for 150 minutes to simulate an ischemic period similar to that occurring during orthotopic (xeno-) heart transplantation. The cannulated pig hearts were then attached to the perfusion system, which was filled with 500cc of freshly drawn human blood, 450cc of hydroxyl ethyl starch 6% (Volulyte, Freseniuns, Bad Homburg, Germany), 5cc of sodium bicarbonate, 8.4%, 0.25cc of 10% calcium gluconate, 1cc of 20% glucose, 1 IU insulin, and 5000 IU heparin (activated clotting times achieved were longer than 400 seconds).
Five healthy male volunteers (blood groups 0, 0, A, A, B; no blood group mismatches, as all of the porcine organs were 0) donated blood twice, once for the control and a second time for a compstatin experiment.
In another control group of autologous ex vivo perfusion, the system was filled with porcine blood of the donor animal. Blood was drawn before and during clamping of the aorta. Heparin, bicarbonate, calcium, and hydroxyethyl starch were added. The perfusate was first circulated in the absence of the donor organ (Fig. 2) 
| Hemodynamic data collection and blood sampling
A time line of the experiments is displayed in Fig. 3 . Samples from the collected human blood were taken at time point T0. Prior to contact with the heart, but after equilibration (temperature, pO 2 , CO 2 , pH, Ca ++ ), samples were taken from the circulating system (T1). Blood samples were taken from the coronary sinus after 10, 30, 60, 90, 120,
The ex vivo perfusion system: Langendorff preparation carried out within the first 15 min (circuit shown in dashed lines): The ascending aorta and the coronary arteries are retrograde-perfused with oxygenated blood. The coronary venous outflow enters the right atrium. The blood is then directed to the rotary pump, the oxygenator, and back to the aorta. Note: the heart is beating but non-working, since the left ventricle remains empty. Biventricular working heart mode in the following 165 min (circuits in violet and red): Oxygenated blood enters the left atrium and is ejected from the left ventricle into the ascending aorta (pre-and afterload may be adjusted by moving the reservoir up or down, by regulating the two damping elements). From the right atrium and ventricle, blood is ejected into the pulmonary artery trunk; the rotary pump supports blood flow to overcome the resistance of the oxygenator and 20μm filter. A heater within the oxygenator system maintains constant blood temperature. Coronary venous blood specimens are drawn from the right atrium via syringe 150, and 180 minutes perfusion (T2-T8). EDTA was added for later complement analysis. All samples were centrifuged at an RCF of 700
for 15 minutes at 4°C to separate plasma from cells; samples were then divided into aliquots and stored at −80°C for further analysis.
Lactate dehydrogenase activity (LDH, commercial assay, clinical laboratory) was measured at T1 and T8. Heart rate (HR), stroke volume index (SVI), cardiac index (CI), and oxygen consumption index (VO 2 )
were measured at the beginning of ex vivo perfusion (T2) at the beginning of working heart mode (T3) and at the end of perfusion (T8).
| Quantitation of Cp40 in plasma
The amount of Cp40 in plasma was determined using solid-phase extraction (SPE) and liquid chromatography-mass spectrometry as previously described.
7,15
| Measurement of activated C3 and the TCC in plasma
Concentrations of activated fragments of human C3 were measured in plasma by a sandwich ELISA as previously described. 9 In brief, microtiter plates were coated with 50 μL of a 2 μg/mL solution of capture antibody C3-28. This antibody specifically recognizes neo-epitopes exposed on molecules of activated C3 (C3b, iC3b, C3c). Wells were then blocked with 1% BSA in PBS for 1 hour, followed by addition of diluted plasma samples and serial dilutions of plasma activated with cobra venom factor (equal to 100% of activated C3) for 1 hour. Bound C3 fragments were detected using a peroxidase-conjugated polyclonal rabbit anti-human C3 IgG (MP Biomedicals). Plates were developed by adding hydrogen peroxide plus 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid according to the manufacturer's instructions (Roche) and read at 405 nm.
Optical density (O.D.) values were converted to percent total C3 activation using the following formula:
sample × 100)]: (dilution curve/dilution sample). 16 At T0, T1, T2, T4, T6, and T8, the TCC of the perfusate was measured using a commercially available ELISA (TCC, Human ELISA kit, HK328-02, Hycult Biotech, Netherlands).
| Thromboelastography
The process of thrombus formation was quantified using thrombelastography at time points T0, T2, T4, and T8. After sampling of 1ml perfusate from the coronary sinus, 1μl protamine was added immediately before thromboelastography (TEG5000, Haemonetics Corporation, MA, USA) was started. The reaction time (R) required to initiate clot formation, kinetic time (K) measuring the speed of clot development, α-angle characterizing the kinetics of clot growth, and the maximum amplitude (MA) describing clot strength were all calculated.
F I G U R E 3 Experimental design of ex vivo perfusion experiments. T0: samples were taken after blood donation. In the treatment group Compstatin Cp40 (32 mg/18 μmol/L) was added to the perfusate before the system was filled (10 min before T1): T1, perfusion begun outside the porcine heart; T2, time point for Langendorff perfusion (beating, non-working mode for a total of 15 min); T3-T8, time points for biventricular working mode T A B L E 1 Left and right ventricular pre-and afterload were kept stable throughout the experiments. Values are given as mean of T2-T8 (ex vivo perfusion) for the aortic pressure and mean of T3-T8 (working heart perfusion) pulmonary artery and atrial pressure Staining intensities were scored semi-quantitatively in a blinded manner using a slide scanner microscope (Hamamatsu, Nanozoomer 2.0-HT, Japan) from 0 to 3 (0=no binding, 3= strong binding of positive control).
| Histology and immunohistochemistry
| Statistics
Data were summarized as arithmetic means and standard deviations. Pearson product-moment correlation coefficients were calculated and linear regression models used to describe relationships between parameters.
| RESULTS
| Hemodynamic parameters
The independent hemodynamic parameters, aortic pressure (62.7 ± 5.2 mm Hg), pulmonary artery pressure (10.8 ± 1.2 mm Hg), left atrial pressure (9.2 ± 0.9 mm Hg), and right atrial pressure (5.4 ± 0.2) were kept stable throughout the Cp40-treated experiments and did not differ from xenoperfused or autologous perfused controls (Table 1 ). Figure 4 shows the variable hemodynamic parameters. At the beginning of reperfusion (T2), the HR in the treated group was lower than in autologous controls, but not different from xenoperfused untreated hearts. At the end of perfusion (T8), the HR exceeded that of untreated controls.
Oxygen consumption was higher in the Cp40-treated group at the end of working heart perfusion (T8), but not during Langendorff perfusion (non-working) at time point T2.
Compared to xenoperfused controls, treated hearts showed a higher stroke volume at the beginning (T3), and a better CI at the beginning and end of working heart perfusion (T3 and T8).
| LDH and lactate
During Cp40-treated perfusion, the LDH concentration in the perfusate remained lower than in xenoperfused and autologous perfused controls (Fig. 4) . While lactate level decreased during autologous perfusion, an increase was seen in xenoperfused experiments. The reduction by Cp40 treatment was not significant (Fig. 4) .
F I G U R E 5 T0, immediately after blood donation (no perfusion of the system); T1, perfusion of the system (no contact to the heart); T2, heart perfusion in Langendorff mode; T4-8, heart perfusion in biventricular working heart mode. 5a: In the untreated xenoperfused group (solid) C3 activation in the perfusate increased when the perfusion of the system was started (T1: 2.8 ± 0.45%, vs T0: 1.15 ± 0.46%, P=.01). At the time points T1-T8 C3 activation was significantly lower in the Cp40-treated group (striped) than in the xeno-perfused control group (P<.05). 5b: After perfusion of the system the concentration of soluble terminal complement complex (sTCC) increased in the perfusate of the xeno-perfused controls (T1: 3940 ± 1735 AU/mL vs T0: 88 ± 50 AU/mL, P<.01) but not in the cpa0 group (T1: 222 ± 15 AU/mL). During perfusion of the heart (T2-T8) the sTCC concentration was significantly lower in the Cp40-treated group (asterisk: P<.05)
| Effect of Cp40 on complement activation
At the beginning of the treatment experiments, Cp40 levels averaged 19.7 ± 3.6 μmol/L; and remained within that range throughout the observation time. Cp40 significantly inhibited C3 activation throughout the experiment compared to controls at the same time points (Fig. 5a ). Compared to samples taken immediately after blood donation, C3 activation only increased in the untreated experiments.
After connection to the perfusion system, sTCC increased in the xenoperfused control group, but not in the treated group. During ex vivo perfusion, sTCC remained significantly lower in the treated group at all time points (Fig 5b) . 
| Correlation and linear regression
| Thromboelastography
There were no differences between the treated and untreated xenoperfused groups (Fig. 7) . The thrombelastographic parameters of the autologous perfused hearts were more stable over time compared with those of the xenoperfusion experiments.
| Histology and immunohistochemistry
Compared to baseline, weights of control hearts had increased at the end of the perfusions by 32 ± 26% (P=.03), whereas weights of Cp40-treated (1 ± 5%, P=.95) and autologous perfused hearts (2 ± 3%, P=.81) showed no change. Consistent with this, histological analysis (Fig. 8) revealed no perivascular edema formation in the treated (x e n op e rfu s io n ) (x e n op e rfu s io n ) (x e n op e rfu s io n ) (x e n op e rfu s io n ) (x e n op e rfu s io n ) ( x e n op e rfu s io n ) 
| DISCUSSION
| The damaging role of complement after xenogeneic heart transplantation
A properly functioning complement system safeguards the integrity of the body's structure by promptly detecting foreign entities and mediating their immediate lysis and removal. 2, 17 When a genetically unmodified foreign organ, such as a heart from a discordant species such as the pig, is perfused with human or other primate blood, it immediately experiences complement-driven hyperacute rejection. 18 Endothelial barrier function is lost, leading to thrombosis, erythrocyte extravasation, edema formation, myocardial damage, and finally irreversible organ dysfunction (reviewed in refs 3, 4 ).
All of these changes, except thrombosis, were seen in the control hearts perfused with our special biventricular working heart system using diluted but freshly drawn human blood. Previous experiments have indicated that the extent of these changes is highly dependent on the particular donor of the blood used for perfusion. We therefore stress that in our experiments all human volunteers donated blood twice, once for the control and once for the Cp40 experiment, and results were compared pairwise. This reduced variation due to immunological differences between blood donors, such as different levels of pre-existing anti-pig antibodies. Blood from donors with known weak xenoreactivity was not used.
Besides the xenoreaction itself, other features of life-supporting cardiac xenotransplantation can induce complement activation, particularly ischemia/reperfusion and contact of blood with plastics and gaseous surfaces within the heart-lung machine 19, 20 (Fig. 1) . In our ex vivo model, these are represented by T1 (complement activation by the perfusion system with the heart excluded), and T2 to T8 the reperfusion of ischemic xenotransplants (control values increase mainly as a result of the non-abrogated xenoantigens). Interestingly, the amount of C3 activation triggered by the perfusion system was higher than subsequent activation by the xenograft (Fig. 5a) . Accordingly, the formation of soluble terminal complement complex increased when the perfusate was circulated and further increased at the time of reperfusion (Fig. 5b ).
In this model, the effect of xenoperfusion on the complement system cannot be investigated in isolation; however, in clinical and preclinical xenotransplantation, both triggers also inevitably arise in combination.
| Blockade of complement activation in a preclinical xenogeneic heart transplantation setting
Inhibition of damaging complement reactions is a major prerequisite for successful clinical cardiac xenotransplantation. Fundamental strategies are genetic ablation of major porcine xenoreactive antigens, principally α-Gal and Hanganutziu-Deicher antigen(Neu5GC), and prevention of coagulation disorders such as thrombotic microangiopathy. 21 These disorders can be prevented by overexpressing human thrombomodulin to supplement activation of protein C. 22, 23 Recently,
Mohiuddin and co-workers had considerable success using triple genetically modified donors (GGTA1-KO/h-thrombomodulin/CD46 complement regulator) for five pig-to-baboon heart transplants. In that study, recombinant cobra venom factor was administered postoperatively for 3 days (day −1, 0, 1) for complement inhibition. 24, 25 Co-stimulation pathway blockade with anti-CD40 was used as the Autologous-perfused hearts (left) and xeno-perfused untreated hearts (middle) served as controls: H&E stained samples revealed no edema formation and less erythrocyte extravasation compared to xeno-perfused controls. The depicted immunohistologically stained examples of the treatment group showed less IgM and fibrinogen deposits compared to xeno-controls. C4d cumulated in the hearts of the treated group, since Cp40 stops the complement pathway at a higher level (C3). The terminal complement complex (C5b-9) is absent in these hearts. Immunohistological differences in the semi quantitative analysis did not reach the level of statistical significance (* P<.05; ** P<.01) total mean survival time of 298 days 26, 27 (personal communication).
The importance of initial complement depletion in the therapeutic regimen used in this experiment is not clear. Its success however indicates that systemic perioperative complement inhibition may also be beneficial when using genetically modified hearts, for example, overexpressing human complement regulator and human thrombomodulin.
However, these hearts were all implanted heterotopically in the abdomen and retrograde-perfused via the abdominal aorta, and so were beating but not ejecting. The Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation has set guidelines for experimental studies prerequisite for commencing clinical trials. 28 Recommendations are as follows: graft survival for at least three postoperative months in 6 of 10 consecutive cases (a target that Mohiuddin′s group has more or less fulfilled), and a life-supporting orthotopic position of the transplanted hearts, or at least a heterotopic intrathoracic position. [29] [30] [31] [32] [33] [34] For both procedures, the use of a heartlung machine, also known to be a complement stimulus, is necessary.
Effective blockade of the complement system is therefore vital, and we anticipate there will be roles for both transgenic expression of complement inhibitors such as human CD46 and administration of soluble complement blockers such as compstatin.
The peptide Cp40 has an advantage over other complement inhibitors such as the monoclonal anti-C5 antibody Eculizumab, 35, 36 because it acts at an earlier stage of the complement cascade and should thus avoid stimulation of additional damaging pathways as a result of additional proinflammatory signals (Fig. 1) . [6] [7] [8] [9] 12 As Cp40 has no relevant adverse effects, as demonstrated by other preclinical and even clinical studies, it could theoretically be used over a longer period after xenotransplantation to overcome humoral rejection.
Cp40 effectively inhibited complement activation, and therefore the triggering of rapid and strong xenogeneic reactions, in all our perfused pig hearts (Fig. 5a ). Consequently, sTCC were almost undetectable in the perfusate (Fig. 5b) and myocardial immunohistochemistry slides (Fig. 8) . The decreased IgM deposition we observed in the treated group might be related to reduced endothelial activation and injury; IgM might bind unspecifically or to newly exposed antigens. At necropsy, hearts treated with Cp40 weighed significantly less than control hearts, as they had less edema and revealed less erythrocyte extravasation, as confirmed by histological examination (Fig. 8) . Functional cardiac parameters such as cardiac index, HR, and SVI were increased; however, they did not reach the level of autologous perfused hearts, indicating that Cp40 does not block the non-complement xenoreactive responses. In the treated hearts, oxygen consumption increased along with improved cardiac work and was compensated by more effective myocardial perfusion (Fig. 4) . Lactate metabolism could not be reversed as in autologous perfused hearts but improved compared to untreated experiments.
| CONCLUSION
Cp40 effectively attenuates complement mediated injury triggered by endothelial antibody binding and extracorporeal circulation.
Cp40 is a promising adjunct for preclinical and future clinical cardiac xenotransplantation.
